Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-28. Numbers and descriptions here follow the published literature rather than marketing material.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Analytical chemistry has applications across science and industry. It is fundamental to forensic science (e.g., DNA fingerprinting and toxicology), bioanalysis (e.g., measuring drug concentrations in pharmacokinetic studies), clinical analysis (e.g., blood glucose monitoring and COVID-19 PCR testing), environmental monitoring (e.g., testing for pollutants in water and air), and materials science (e.g., quality control of semiconductors and nanomaterials). Great effort is being put into shrinking the analysis techniques to chip size. Although few examples of such systems compete with traditional analysis techniques, potential advantages include size/portability, speed, and cost. Micro total analysis system (μTAS) or lab-on-a-chip. Microscale chemistry reduces the amount of chemicals used. Many developments improve the analysis of biological systems. Examples of rapidly expanding fields in this area are genomics, DNA sequencing and related research in genetic fingerprinting and DNA microarray; proteomics, the analysis of protein concentrations and modifications, especially in response to various stressors, at various developmental stages, or in various parts of the body; metabolomics, which deals with metabolites; transcriptomics, including mRNA and associated fields; lipidomics, dealing with lipids and its related fields; peptidomics, dealing with peptides and its related fields; and metallomics, dealing with metal concentrations and especially with their binding to proteins and other molecules.
FutureFeed is a ruminant livestock feed ingredient based on seaweed that can reduce methane emissions, established by Australia's Commonwealth Scientific and Industrial Research Organisation (CSIRO). FutureFeed holds the global intellectual property to use the seaweed Asparagopsis for livestock feed. Lowered methane emissions can be achieved by the addition of a small amount of the seaweed into the daily diet of livestock. This discovery was made by a team of scientists from CSIRO and James Cook University (JCU), supported by Meat & Livestock Australia (MLA), who came together in 2013 to investigate the methane reduction potential of various native Australian seaweeds. Asparagopsis is a genus of red algae, endemic in many parts of the world including Australia. The seaweed has proven to be the most efficient natural supplement available for lowering methane from ruminant livestock. It also has feed efficiency benefits. The active ingredient in seaweed is bromoform, which inhibits a key enzyme for methanogenesis.
== Principle of operation == Several steps are involved in electron transfer dissociation. Usually a protein mixture is first separated using high performance liquid chromatography (HPLC). Next multiply-protonated precursor molecules are generated by electrospray ionization and injected into the mass spectrometer. (Only molecules with a charge of 2+ or greater can be used in ETD.) In order for an electron to be transferred to the positive precursor molecules radical anions are generated and put into the ion trap with them. During the ion/ion reaction an electron is transferred to the positively-charged protein or peptide, causing fragmentation along the peptide backbone. Finally the resultant fragments are mass analyzed.
Sources: en.wikipedia.org
Wing Commander Christopher Andrew Wright, , Royal Air Force, 2653992B. Civil James Martin Ainscough. Lately Chief Executive Officer, Help Musicians. For services to Music and Musicians. Heather Margaret Patricia Akehurst. Chief Executive, Open Awards. For services to Further Education in Merseyside. Edward Jonathan Corcos Album. Founder, The Settle and Carlisle Railway Trust. For services to Railway Heritage and to the communities in the North of England. Genethlios Michael Anastassiades. Product and Lighting Designer. For services to Design. Andrew Robert James Anderson. Head, Maggie's Cancer Support Centre. For services to Cancer Support in the UK and Abroad. Dr. Claire Elizabeth Armstrong. Chief Executive Officer, Royal British Legion Scotland. For services to Veterans in Scotland. Nigel Christopher Ashton. Councillor, North Somerset Council. For Political and Public Service. Duncan Roy Barber. For services to the Defence Industry. Virginia Barrett. Principal and Chief Executive Officer, Farnborough College of Technology. For services to Further Education. Tiffany Crowell Beck. Chair of Trustees, Maritime Academy Trust. For services to Education. Elaine Bedell. Chief Executive Officer, Southbank Centre. For services to Business and to the Arts. Baldev Parkash Bhardwaj. For services to the community in Oldbury, West Midlands. Professor Maurice Biriotti. Chief Executive Officer, SHM Productions and Professor of Applied Humanities, University College London. For services to Business, to Academia and to Philanthropy. Antony Kenneth Blackburn. Broadcaster.
=== Imaging Methods Core Facility === The Integrated Microscopy Core Facility (IMCF) provides fluorescence microscopy, electron microscopy, and flow cytometry services. The facility offers training, instrument access, and consulting services for experimental design, sample preparation, and data analysis. It also organizes courses on microscopic techniques.
==== Weak partial androgenic activity ==== CPA, like spironolactone and other steroidal antiandrogens such as chlormadinone acetate and megestrol acetate, is actually not a pure antagonist of the AR – that is, a silent antagonist – but rather appears to be a very weak partial agonist. Clinically, CPA generally functions purely as an antiandrogen, as it displaces much more efficacious endogenous androgens such as testosterone and DHT from interacting with the receptor and thus its net effect is virtually always to lower physiological androgenic activity. But unlike silent antagonists of the AR like nonsteroidal antiandrogens such as flutamide, bicalutamide, and enzalutamide, CPA, by virtue of its slight intrinsic activity at the AR, may be unable to fully inhibit androgenic signaling in the body, which may persist to an extent in some tissues such as the prostate gland. In accordance with its albeit weak capacity for activation of the AR, CPA has been found to stimulate androgen-sensitive carcinoma growth in the absence of other androgens, an effect which could be blocked by co-treatment with flutamide. In one study in rodents, DHT-stimulated prostate weight remained 40% above controls with administration of CPA even at the highest dosage, while flutamide was able to completely block the stimulatory effects of DHT. In addition, CPA alone increased prostate weight by 60%, whereas flutamide had no effect.
==== World War II ==== By World War II, rations had taken modern organized forms for both the Allies and the Axis. The United States Armed Forces revised their World War I-era ration organization system into an alphabetized system: A-rations of fresh food, B-rations of packaged unprepared food, C-rations of prepared canned food, D-rations of chocolate, and K-rations of three-course meals. The US military also issued the 10-in-1 food parcel, designed to supply ten soldiers. A-rations, designed for troops in garrison, included foods such as fresh meat, vegetables, fruits, coffee, and sugar. B-rations, intended for preparation by cooks in field kitchens, contained essentially the same types of foods as A-rations except canned for better preservation. C-rations, intended for troops in the field lacking access to fresh or packaged unprepared food, contained several variations of food combinations, among them meat and beans (including pork and beans), ham, eggs, and potatoes, and chicken and vegetables. D-rations consisted of chocolate bars designed to give needed calories in case soldiers in the field were isolated from any other food source. K-rations were issued to mobile soldiers such as paratroopers, tank crews, and motorcycle couriers. They contained foods such as canned meat, with some canned meat issued together with eggs, carrot or apple, sugar or malted milk tablets, fruit bars, oatmeal, cheese, biscuits, powdered fruit drinks, salt, and chewing gum.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.